Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. - Wikidata - wikimedia - TriplyDB

Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.

Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.

http://www.wikidata.org/entity/Q34075502

about

Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30 Bile acids: regulation of apoptosis by ursodeoxycholic acid Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice Mouse models of polyglutamine diseases: review and data table. Part I Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases Bile Acids in Neurodegenerative Disorders Tauroursodeoxycholic acid prevents hearing loss and hair cell death in Cdh23(erl/erl) mice.Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans.Extensive alterations of blood metabolites in pediatric cerebral malaria.Chemoproteomic Profiling of Bile Acid Interacting Proteins Therapeutic Strategies in Huntington's Disease Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease Administration of Tauroursodeoxycholic Acid Attenuates Early Brain Injury via Akt Pathway Activation Tauroursodeoxycholic acid (TUDCA) protects photoreceptors from cell death after experimental retinal detachment Waking action of ursodeoxycholic acid (UDCA) involves histamine and GABAA receptor block.Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway.Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease.Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations.Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial Experimental therapeutics in transgenic mouse models of Huntington's disease.TUDCA slows retinal degeneration in two different mouse models of retinitis pigmentosa and prevents obesity in Bardet-Biedl syndrome type 1 mice.Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease.Novel therapeutic targets for Huntington's disease.Therapeutics development for triplet repeat expansion diseases.The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats.Potential for therapeutic manipulation of the UPR in disease.Effect of a chemical chaperone, tauroursodeoxycholic acid, on HDM-induced allergic airway disease.Neuroprotection for Huntington's disease: ready, set, slow Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells.Emerging drug therapies in Huntington's disease.Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going?Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.Antioxidants in Huntington's disease.Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

P2860

Q24649167-0341B35A-6DFE-4F44-9AB7-3186E0191ED0 Q24653969-463348EA-D94A-4267-970B-ABAACF496684 Q24795623-51A57643-0DF8-4337-A230-E020C79E1D61 Q26853025-5530BA04-FA06-4D86-9568-62F5F9966789 Q27005950-386DC3DB-B77D-437F-B909-45C5F6FA7C67 Q27026087-AD9EA068-A2C3-4CC2-838A-89DCDABC852E Q28078549-7F878ABB-A341-48A5-B45B-E91055E212E8 Q30362420-DA0147AB-934D-400E-AC44-CBE8B61EAFE7 Q33225632-F0E28B61-5B8C-4E7F-9A11-6B99B7A350A2 Q33584763-B0267D80-9264-4656-A757-1B874FA365D1 Q33731122-B7EF0932-AD04-4664-B2E6-7BC49CDC3943 Q33790829-34B582F3-BF2F-43E7-B476-E5036742B98A Q33812932-4A60E833-EB27-4571-9F40-D2AC6141B149 Q33844975-297ABA5C-97F3-47A5-B847-DA7F6D420D20 Q33875231-A664DC14-625E-4709-9D84-0118F69658D9 Q34035789-06FA98A1-70D5-4AF2-96FB-95D6AB0A7FAB Q34374211-AA3309F9-3813-4EDB-A14C-07FE9CC606B8 Q34520873-DBFF69C9-F8EF-44BC-9172-BA18E3949A37 Q34977478-1500F189-D61D-40FB-B5E7-7808CB78716E Q35022852-41E33D08-DB84-4010-ABA1-C48D1469328F Q35095142-11D3C034-079E-4131-8777-109F97C755D3 Q35172521-C0041F29-079C-452C-8805-D5B671A17CCA Q35515556-A65B7F3D-81CF-45A3-806F-5BA585BE45CA Q35730907-34988CC2-732C-4136-9A9E-CF70E3010C6C Q35752429-53E4AC78-7EF0-4AC0-A4E2-D9924C8D13C4 Q35797129-F60A49E5-0550-4FD5-85EF-ABCB834E8B90 Q35861134-5DE9198B-9A99-4F9A-816C-0C88A1DA0EBA Q36219680-E7B4D21A-BDEC-439B-958C-FF0F0C540563 Q36277195-155A42B3-AB48-43E2-909E-91FB5C906447 Q36358871-CEA41506-9E51-495C-B913-2F5F5DE03715 Q36380667-15CC5A55-DE33-476A-A70F-20169DB3FC72 Q36809416-9E75F60F-4006-47CA-846A-42B772223359 Q37071741-EE92074E-7E77-4153-9DFE-2468224C3B33 Q37131243-3DA399D7-9ADE-4717-8F47-BFB1D6755A7C Q37384925-D2FE78B0-99F9-416A-B30F-E8546D113D95 Q37488273-764C6EBA-D887-4882-BF0F-FCF6E1C2F79D Q37735565-5F44DA2D-A470-4848-ACF8-654614192099 Q37919924-16D6F907-9EE5-408F-ABE1-017323833018 Q37964359-EE3CF547-3BDE-459C-A121-EF9D056EAFC7 Q38013005-350B4362-16A0-40D8-B460-F33EF49D4688

P2860

Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.

http://www.wikidata.org/entity/Q34075502

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease.

@ast

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease.

@en

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease.

@nl

type

label

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease.

@ast

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease.

@en

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease.

@nl

prefLabel

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease.

@ast

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease.

@en

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease.

@nl

P1433

Q34075502-96196B94-2A50-44E4-AF31-A6A15642F6B3

P1476

Q34075502-199F075B-3C88-473C-8D0C-C6AD456944DB

P2093

Q34075502-00E42FC9-37CB-4485-B6CC-BF5DB9819B50

Q34075502-4A559719-6B3E-423D-A9A2-A896864B74C8

Q34075502-7F7DA260-6ED2-4B96-A27C-7735269DDEAB

Q34075502-D616A0BF-8B60-4523-A71C-B30A460EF457

P2860

Q34075502-0407779B-348F-4686-B7A4-E662C33AA618

Q34075502-079763C3-284C-4D38-B654-9544E02F80C0

Q34075502-0ADEE951-C13A-4BBD-95E1-6B240443DD01

Q34075502-11033509-7185-46F9-AF97-0C9AD633B7F4

Q34075502-18D9E682-8140-4F2F-9E98-404B5E92DD3B

Q34075502-2328BE7F-9AC4-40A4-9792-F96D6F6D926E

Q34075502-23E71677-B7A0-4FA1-BA51-F8442FC2A95B

Q34075502-2ECDFABC-90E7-4194-9311-BFADECE46DFA

Q34075502-405B2831-B13C-4686-978B-A206D97312CC

Q34075502-453F60AF-A4EE-441E-8424-9CBCD757645A

P304

Q34075502-1E432C40-416F-4915-ACB7-BA295A5E52A9

P31

Q34075502-972CA759-2F71-42F5-8786-756028A2D717

P356

Q34075502-925C87E5-460A-4953-AFDD-DF9D41B26148

P407

Q34075502-AEAB544A-0CC3-49A9-AAC7-54F30E57D1BC

P433

Q34075502-FF6FBE62-7E39-465D-90F9-45D17ED3829A

P478

Q34075502-AB72F6D3-8B22-4FF3-A99A-6849EB930D50

P50

Q34075502-5ADA38A0-7480-49AF-AD7A-5DB1A44B9E14

Q34075502-7ED3CFE5-4BFA-4D60-A56B-B0F01705CA36

P577

Q34075502-B6E394A3-2BC0-4BB9-947C-07D16A5BFD20

P5875

Q34075502-FFC62406-471B-4F2F-9765-A3ABD176C44B

P698

Q34075502-BD45F9BD-0076-45AC-8A60-A5530F4730F8

P921

Q34075502-A56A91AA-D60E-41A2-8AA7-F24D147F34D9

P932

Q34075502-F387AE24-0DF4-4B50-942C-914CD2E78056

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Tauroursodeoxycholic acid, a b ...... model of Huntington's disease

@en

P2093

Clifford J Steer

http://www.w3.org/2001/XMLSchema#string

Manik S Chhabra

http://www.w3.org/2001/XMLSchema#string

Tacjana Eich

http://www.w3.org/2001/XMLSchema#string

Walter C Low

http://www.w3.org/2001/XMLSchema#string

P2860

Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation

Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate.

Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease

P304

10671-10676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.162362299

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Cecilia Rodrigues

P577

2002-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11234210

http://www.w3.org/2001/XMLSchema#string

P698

12149470

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

125009

http://www.w3.org/2001/XMLSchema#string